Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MRK and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MRK and 80,000+ other tickers.
See exactly how MRK's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MRK and 80,000+ other tickers.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of…
Andra AP fonden trimmed its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 14.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 364,485 shares of the company's stock after selling 63,615 shares during the period. Merck and Co., Inc. makes up about
Merck (MRK) concluded the recent trading session at $124.4, signifying a -2.43% move from its prior day's close.
For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16, 2026, when the U.S. Food and Drug Administration approved the first oral PCSK9 inhibitor, a class of powerful cholesterol drugs that until now existed only as an injection.
PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.
Dimensional Fund Advisors LP lifted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 23.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,456,039 shares of the company's stock after acquiring an additional 2,969,856 shares during the quarter. Merck